Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 146Carcinoma, Non-Small-Cell Lung 112Carcinoma, Renal Cell 74Neoplasm Metastasis 53Carcinoma, Hepatocellular 51Squamous Cell Carcinoma of Head and Neck 50Lung Neoplasms 48Colorectal Neoplasms 34Pancreatic Neoplasms 30Neoplasms 30Hodgkin Disease 30Urinary Bladder Neoplasms 24Sarcoma 23Brain Neoplasms 23Stomach Neoplasms 22Head and Neck Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Carcinoma, Transitional Cell 20Glioblastoma 19Recurrence 17Colonic Neoplasms 17Kidney Neoplasms 16Uveal Melanoma 15Small Cell Lung Carcinoma 15Multiple Myeloma 15Esophageal Neoplasms 15Carcinoma, Squamous Cell 14Skin Neoplasms 13Leukemia, Myeloid, Acute 13

Interventions

Rituximab 77Cyclophosphamide 54fludarabine phosphate 50Peripheral Blood Stem Cell Transplantation 44Mycophenolic Acid 34Whole-Body Irradiation 33Tacrolimus 25Cyclosporine 23Busulfan 22Bortezomib 22Dexamethasone 21Etoposide 19ibrutinib 18Melphalan 17Antilymphocyte Serum 17Methotrexate 15Lenalidomide 15Filgrastim 14Radiotherapy 12Bendamustine Hydrochloride 12Sirolimus 10Calcium Dobesilate 10Flow Cytometry 9Everolimus 9Cyclosporins 9zanubrutinib 8Alemtuzumab 7ibritumomab tiuxetan 6Transplantation 6Therapeutics 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Waldenstrom Macroglobulinemia × Nivolumab × Clear all
NCT03015896 2025-09-29

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Active not recruiting
36 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡